PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review.

MRI PI-RADS biopsy avoidance biparametric MRI dynamic contrast-enhanced gadolinium contrast medium multiparametric MRI prostate cancer risk stratification unenhanced MRI

Journal

AJR. American journal of roentgenology
ISSN: 1546-3141
Titre abrégé: AJR Am J Roentgenol
Pays: United States
ID NLM: 7708173

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 20 8 2020
medline: 18 2 2021
entrez: 20 8 2020
Statut: ppublish

Résumé

The steadily increasing demand for diagnostic prostate MRI has led to concerns regarding the lack of access to and the availability of qualified MRI scanners and sufficiently experienced radiologists, radiographers, and technologists to meet the demand. Solutions must enhance operational benefits without compromising diagnostic performance, quality, and delivery of service. Solutions should also mitigate risks such as decreased reader confidence and referrer engagement. One approach may be the implementation of MRI without the use gadolinium-based contrast medium (bipara-metric MRI), but only if certain prerequisites such as high-quality imaging, expert interpretation quality, and availability of patient recall or on-table monitoring are mandated. Alternatively, or in combination, a clinical risk-based approach could be used for protocol selection, specifically, which biopsy-naive men need MRI with contrast medium (multiparametric MRI). There is a need for prospective studies in which biopsy decisions are made according to MRI without contrast enhancement. Such studies must define clinical and operational benefits and identify which patient groups can be scanned successfully without contrast enhancement. These higher-quality data are needed before the Prostate Imaging Reporting and Data System (PI-RADS) Committee can make evidence-based recommendations about MRI without contrast enhancement as an initial diagnostic approach for prostate cancer workup.

Identifiants

pubmed: 32812795
doi: 10.2214/AJR.20.24268
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3-19

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Ivo G Schoots (IG)

Department of Radiology & Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Jelle O Barentsz (JO)

Department of Radiology, Nuclear Medicine & Anatomy, Radboud University Medical Center, Nijmegen, The Netherlands.

Leonardo K Bittencourt (LK)

Dasa Company, Rio de Janeiro, Brazil.
Fluminense Federal University, Rio de Janeiro, Brazil.

Masoom A Haider (MA)

Joint Department Medical Imaging, Sinai Health System, University Health Network, University of Toronto, Toronto, ON, Canada.

Katarzyna J Macura (KJ)

Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.

Daniel J A Margolis (DJA)

Department of Radiology, Weill Cornell Medical College, New York, NY.

Caroline M Moore (CM)

Department of Urology, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

Aytekin Oto (A)

Department of Radiology, University of Chicago Medicine, Chicago, IL.

Valeria Panebianco (V)

Department of Radiological Sciences, Oncology & Pathology, Sapienza University of Rome, Rome, Italy.

Mohummad M Siddiqui (MM)

Department of Surgery, Division of Urology, University of Maryland School of Medicine, Baltimore, MD.

Clare Tempany (C)

Department of Radiology, Brigham and Women's Hospital, Boston, MA.

Baris Turkbey (B)

Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Geert M Villeirs (GM)

Division of Genitourinary Radiology, Ghent University Hospital, Ghent, Belgium.

Jeffrey C Weinreb (JC)

Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT.

Anwar R Padhani (AR)

Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH